<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Vast Therapeutics</title>
    <link>https://www.biospace.com/employer/3076406/vast-therapeutics</link>
    <description>Vast Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Fri, 01 Jul 2022 16:56:07 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076406/vast-therapeutics.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Vast Therapeutics Presents Promising Preclinical Results for Novel Treatment for NTM Disease</title>
      <link>https://www.biospace.com/vast-therapeutics-presents-promising-preclinical-results-for-novel-treatment-for-ntm-disease</link>
      <description>Vast Therapeutics announces promising results with a nitric oxide releasing drug candidate under investigation for infections caused by Mycobacterium abscessus, a multi-drug resistant bacteria for which there are currently no FDA-approved treatments.</description>
      <pubDate>Fri, 01 Jul 2022 16:56:07 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-presents-promising-preclinical-results-for-novel-treatment-for-ntm-disease</guid>
    </item>
    <item>
      <title>Vast Therapeutics Announces Publication of Potential New Treatment for Non-tuberculosis Mycobacteria Infections</title>
      <link>https://www.biospace.com/vast-therapeutics-announces-publication-of-potential-new-treatment-for-non-tuberculosis-mycobacteria-infections</link>
      <description>Vast Therapeutics announces publication of a manuscript in the journal of Antimicrobial Agents &amp; Chemotherapy describing the utility of its novel nitric oxide-releasing drug candidate targeting infections caused by non-tuberculosis mycobacteria.</description>
      <pubDate>Wed, 17 Jan 2024 14:36:04 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-announces-publication-of-potential-new-treatment-for-non-tuberculosis-mycobacteria-infections</guid>
    </item>
    <item>
      <title>Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer</title>
      <link>https://www.biospace.com/vast-therapeutics-expands-leadership-team-with-appointment-of-dr-paul-bruinenberg-as-chief-medical-officer</link>
      <description>Vast Therapeutics today announced the addition of Paul Bruinenberg , MD, MBA as Chief Medical Officer.</description>
      <pubDate>Thu, 07 Mar 2024 14:06:06 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-expands-leadership-team-with-appointment-of-dr-paul-bruinenberg-as-chief-medical-officer</guid>
    </item>
    <item>
      <title>Vast Therapeutics Selected to Present at the American Thoracic Society (ATS) 2024 Respiratory Innovation Summit</title>
      <link>https://www.biospace.com/vast-therapeutics-selected-to-present-at-the-american-thoracic-society-ats-2024-respiratory-innovation-summit</link>
      <description>Vast Therapeutics, a clinical-stage life science company focused on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases, today announced an upcoming presentation at the 2024 Respiratory Innovation Summit being held in San Diego May 17-18, 2024.</description>
      <pubDate>Wed, 17 Apr 2024 14:06:05 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-selected-to-present-at-the-american-thoracic-society-ats-2024-respiratory-innovation-summit</guid>
    </item>
    <item>
      <title>Vast Therapeutics (formerly Novoclem) Announces Results Showing Eradication of all In Vitro Tested Multi-Drug Resistant Bacteria and a 99% Reduction of Nontuberculous Mycobacteria (NTM) in Animal Model.</title>
      <link>https://www.biospace.com/vast-therapeutics-formerly-novoclem-announces-results-showing-eradication-of-all-in-vitro-tested-multi-drug-resistant-bacteria-and-a-99-percent-reduction-of-nontuberculous-mycobacteria-ntm-in-animal-model</link>
      <description>Broad Action Against Multidrug Resistant Pathogens Leads to Name Change from Novoclem Therapeutics to Vast Therapeutics.</description>
      <pubDate>Tue, 22 May 2018 12:06:59 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-formerly-novoclem-announces-results-showing-eradication-of-all-in-vitro-tested-multi-drug-resistant-bacteria-and-a-99-percent-reduction-of-nontuberculous-mycobacteria-ntm-in-animal-model</guid>
    </item>
    <item>
      <title>Vast Therapeutics Announces Series A Funding</title>
      <link>https://www.biospace.com/vast-therapeutics-announces-series-a-funding</link>
      <description>Partnership with Shionogi Ltd Includes Collaboration for Development of Proprietary Nitric Oxide Powder Technology for Antimicrobial Resistant Bacteria in Respiratory Applications</description>
      <pubDate>Wed, 05 Dec 2018 14:16:13 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-announces-series-a-funding</guid>
    </item>
    <item>
      <title>Vast Therapeutics Announces Funding from Cystic Fibrosis Foundation for Further Development of BIOC51</title>
      <link>https://www.biospace.com/vast-therapeutics-announces-funding-from-cystic-fibrosis-foundation-for-further-development-of-bioc51</link>
      <description>Award Supports Advancement of BIOC51 Through Toxicology Studies in 2019</description>
      <pubDate>Thu, 13 Dec 2018 13:36:16 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-announces-funding-from-cystic-fibrosis-foundation-for-further-development-of-bioc51</guid>
    </item>
    <item>
      <title>Vast Therapeutics Receives Qualified Infectious Disease Product Status for BIOC11</title>
      <link>https://www.biospace.com/vast-therapeutics-receives-qualified-infectious-disease-product-status-for-bioc11</link>
      <description>Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, announced that another of its drug candidates, BIOC11, has been designated as a "Qualified Infectious Disease Product" by the U.S. Food and Drug Administration.</description>
      <pubDate>Tue, 08 Oct 2019 13:06:06 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-receives-qualified-infectious-disease-product-status-for-bioc11</guid>
    </item>
    <item>
      <title>Vast Therapeutics Announces BIOC11 testing results for Nontuberculous Mycobacteria (NTM) in Animal Model</title>
      <link>https://www.biospace.com/vast-therapeutics-announces-bioc11-testing-results-for-nontuberculous-mycobacteria-ntm-in-animal-model</link>
      <description>Vast's Second Drug Candidate achieves 99% reduction of NTM</description>
      <pubDate>Tue, 22 Oct 2019 13:16:05 GMT</pubDate>
      <guid>https://www.biospace.com/vast-therapeutics-announces-bioc11-testing-results-for-nontuberculous-mycobacteria-ntm-in-animal-model</guid>
    </item>
    <item>
      <title>Vast Awarded $2 Million Grant to Combat Deadly Respiratory Bacteria</title>
      <link>https://www.biospace.com/press-releases/vast-awarded-2-million-grant-to-combat-deadly-respiratory-bacteria</link>
      <description />
      <pubDate>Wed, 22 Jan 2025 06:23:53 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/vast-awarded-2-million-grant-to-combat-deadly-respiratory-bacteria</guid>
    </item>
  </channel>
</rss>
